GHK-Cu and SNAP-8 Interaction: Compatible | Peptide Database

Reassess for infection or underlying metabolic factors first. GHK-Cu accelerates normal healing. It doesn't override systemic barriers like uncontrolled diabetes, smoking, or zinc deficiency. If the wound shows signs of infection (purulent drainage, expanding erythema, fever), address that before continuing peptide therapy. If metabolic factors are ruled out, extending GHK-Cu application to 14 days may help, but diminishing returns set in after the proliferative phase ends.

GHK-Cu's effect is self-limiting through negative feedback. The peptide doesn't suppress MMPs below baseline physiological levels. It restores the MMP/TIMP ratio to a homeostatic range. In young, healthy fibroblasts with already-balanced MMP/TIMP expression, GHK-Cu produces minimal change because the transcription factors it modulates aren't hyperactive. The regulatory effect is most pronounced in aged, photo-damaged, or inflamed tissue where MMP overexpression is driving pathology. This makes GHK-Cu a corrective agent rather than a universal MMP suppressor, which is why it doesn't impair normal tissue remodeling processes.

Verify copper:peptide molar ratio is 1:1 or higher using atomic absorption spectroscopy before proceeding with receptor studies. Undersaturated GHK loses 80–90% of its integrin-binding affinity because the square planar copper geometry is required for the bioactive conformation. Apo-GHK (copper-free) binds weakly and non-specifically. Commercial peptide suppliers sometimes ship lyophilized GHK with copper acetate or copper chloride listed separately; you must verify complete complexation, typically achieved by dissolving both components in pH 7.4 buffer and incubating for 30 minutes at room temperature before dilution to working concentrations.

Draw the precise dose needed and inject immediately—don't store drawn solution in the larger syringe. The 2–2.5mL of air space in a 3mL syringe accelerates copper oxidation through oxygen contact. If you must use a 3mL syringe, draw the bacteriostatic water first to fill the dead space, then draw the GHK-Cu dose, and inject within 5 minutes. This isn't ideal—oxygen has already contacted the solution—but it limits exposure time. For any protocol requiring pre-drawn syringes or delayed administration, switch to 1mL insulin syringes. The cost difference is negligible, and oxidation losses from improper syringe volume easily exceed the cost of appropriate supplies.

The peptide sequence (Gly-His-Lys) without copper chelation has minimal biological activity—microarray studies confirm this. If the product label lists only 'GHK' or 'copper peptide' without stating copper(II) molar ratio, assume incomplete coordination. Properly formulated GHK-Cu should specify the copper salt used (typically copper sulfate or copper chloride) and maintain a 1:1 peptide-to-copper molar ratio. Concentrations below 0.1% may be subtherapeutic regardless of formulation.